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A B S T R A C T
Prevention of obesity may help reduce the morbidity and mortality from cardiovascular diseases. In Croatia, over half
of adult population is overweight. Aldo the basic medical principles of healthy weight-loss programmes are well known,
it is believed that mainly because of the leak of successful therapeutic approach obesity remains the most challenging
changeable cardiovascular risk factor in nowadays clinical practice. Objective of this Croatian Healthy Weight Loss
Programme substudy was to determine effects and differences between the intensive group and intensive individual
weight-loss program on weight loss and cardiovascular risk factor. A clinical trial included 476 adults whose body mass
index (BMI) was >30 or >28 accompanied by increased blood pressure, glucose, and cholesterol. The study participants
completed either a group (n=243) or individually-based (n=233) 6-month weight-loss program consisting of education,
low-fat diet, pharmacological treatment with orlistat, psychological counselling, and exercise. Body weight, body mass
index, blood pressure, blood sugar, and blood cholesterol were measured in all participants after 3 and 6 months. The av-
erage weight loss was 12.2 (13%) kg and 7.6 (9%) kg in the group and individual program, respectively. Beside the
weight reduction, the levels of blood cholesterol, glucose, and blood pressure were also significantly reduced in compari-
son with baseline, decreasing to normal values in all participants (P<0.001 for all). Decrease in the monitored parame-
ters was greater in participants in the group program. The weight loss program provided a healthy loss of extra weight in
the period of 6 months. The group program produced greater decrease in body weight, body mass index, blood pressure,
glucose, and cholesterol than the individual program.
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Introduction
Obesity ranks alongside smoking as one of the most
important risk factors for cardiovascular diseases, which
are still a very frequent cause of death in industrially de-
veloped countries1–4. According to the available data for
transitional countries, approximately 60–70% of the pop-
ulation suffers from overweight5,6. In Croatia, 79% of
men and 50% of women are overweight6. Moreover, in
the past few years, the morbidity and mortality from car-
diovascular diseases in Croatia has increased, while Eu-
rope and the USA are marking the declining trend3–7. It
is estimated that treating obesity and obesity-related
complications accounts for 2–7% of the total costs of
healthcare8–10.
The Croatian national strategy for the prevention of
cardiovascular diseases strongly supports programs deal-
ing with the adoption of healthy habits as the least ex-
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pensive mechanism for reducing cardiovascular morbid-
ity and mortality. The programs based on the proper
nutrition, reduction in the intake of fats, and change in
behaviour make an integral part of this process11. Al-
though the scope of the problem of obesity treatment in-
creasingly requires an out-patient approach under the
supervision of the family doctor, the majority of obesity
treatment studies so far have been conducted in hospital
conditions under the supervision of specialized hospital
services. As previously demonstrated in the Croatian
Healthy Weight Loss Program Study12, the six-month
outpatient intensive weight loss treatment based on the
healthy diet, fat reduction, psychological counselling,
regular exercise training and orlistat administration is
efficient in weight loss and reduction of blood pressure,
fasting blood glucose and total cholesterol. The aim of
this substudy was to determine the possible differences
between group and individual treatment of obesity, as
well as to compare the results of the cardiovascular risk
factor reduction provided through individual work with
the results of the programme provided through group
work.
Subjects and Methods
The study included 627 persons who successfully
completed the Healthy Weight Loss Program between
September 1, 2000 and December 31, 2004. By their own
choice, participants were divided in a group (n=243) or
individual (n=233) programme. The study participants
were aged between 18 and 65 and had a body mass index
(BMI) over 30 or BMI over 28 accompanied by increased
blood pressure, sugar and/or cholesterol.
At the beginning of the Program, all participants at-
tended a one-day interactive workshop given by the au-
thors of the study, general practitioners, specialists in in-
ternal medicine, pharmacists, nutritionists, psychiatrists,
and sports medicine specialists. The workshop consisted
of lectures followed by the discussion on the reasons for
overweight, its complications, and treatment options ran-
ging from proper diet to regular exercise to pharma-
cotherapy. Information on healthy weight loss strategies
was also provided in a form of written educational mate-
rial and a weight loss guide, Take Control of Your Body
Weight13. Height, weight, waist circumference, and BMI
were measured in all participants, whereas data on hy-
pertension, increased blood sugar and cholesterol were
collected from the medical records. After the workshop,
the participants were free to chose whether to continue
the program through individual or group work.
The program lasted 6 months and consisted of heal-
thy diet education, psychotherapeutic counselling, physi-
cal exercise, reduction diet, and pharmacological treat-
ment with orlistat. All patients received detailed written
instructions on nutrition and physical activity as well as
information on the body weight control program.
Participants in the group program (n=320) were di-
vided in groups of 10, which gathered every 4 weeks for
2-hour thematic meetings to discuss the reasons for obe-
sity, health complications of obesity, nutrition, treatment
with orlistat, physical activity, and the psychology of
overweight people and methods to keep the achieved
body weight. Group meetings were moderated by the au-
thors of the study and attended by psychologists, psychi-
atrists, nutritionists, and family doctors, and specialists
in internal and sports medicine. After the meeting, one
academic hour was dedicated to an interactive conversa-
tion on the topic of the meeting. Particular attention was
given to the analysis of previous unsuccessful attempts
to decrease body weight. If desired, participants could
bring a friend or family member to group meetings. Par-
ticipants in the individual program (n=307) saw their
physician once a month for a medical check up and dis-
cussion about the various aspects of treating obesity in-
stead of participating in group meetings.
During the program, all participants were on a mild
hypocaloric diet (1600 kcal/day) containing not more
than 30% of fat. After a 4-week adjustment to the diet,
psychotherapy support, and nutritional education, they
started taking orlistat (3´120 mg/day), a lipase inhibitor
reducing fat absorption from the digestive system, three
times a day with a meal. No appetite suppressors were al-
lowed during the Program. All participants were re-
quired to keep a journal on their daily nutrition, physical
activities, and problems that appeared during the course
of the program.
Height, body weight, BMI, waist size, complete labora-
tory blood analysis, and blood pressure were monitored
in all patients on monthly basis. Laboratory tests were
conducted twice during the study, in weeks 12 and 24.
During the 6-month program, 77 participants dro-
pped out from the group and 74 from the individual pro-
gram. The final analysis included 476 participants who
completed the program, i.e., 233 in the individual and
243 in the group program (Table 1).
Statistical analyses were performed with baseline da-
ta and data obtained at weeks 12 and 24. Data were pre-
sented as mean values with standard deviations (±SD).
For the comparison of two groups, the t-test was used,
whereas for the comparison of mean values for several
groups, the analysis of variance (ANOVA) and the Dun-
can test for multiple comparison were applied. Differ-
ences in the distribution of categorical variables were an-
alyzed with c2-test. The characteristics that significantly
differed between the groups at the beginning of the pro-
gram were compared by using analysis of covariance
(ANCOVA). All statistical tests were performed with
SAS© System, ver. 8.2 (SAS Institute Inc., Cary, NC,
USA), with the level of significance set at 0.05.
Results
At baseline, participants in the group program did not
differ from participants in the individual program in
their age and values of blood pressure, glucose, and cho-
lesterol (Table 1). However, the participants in the group
program had a significantly greater BMI, body height,
body weight, and waist circumference than the partici-
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pants in the individual program. There were also signifi-
cantly more men among the participants in the group
program.
At week 12, the body weight and BMI were still signif-
icantly greater in participants in the group program than
participants in the individual program (Table 1). At week
24, there was no difference in BMI between the two
groups, but the difference in body weight remained. Al-
though blood pressure and glucose were statistically hi-
gher at week 24 in the participants in the group program
than in the participants in the individual program, the
values of these parameters in both groups decreased and
were within normal range.
Overall, almost half of all participants lost 5–10% of
their baseline weight by week 12 and over 10% of base-
line weight by week 24 (Table 2). Participants in the
group program had significantly greater weight loss than
participants in the individual program both at week 12
and at week 24 (p<0.001, c2-test).
As there were differences between the groups at the
beginning of the program, the corresponding changes in
monitored parameters were compared instead of their
values at weeks 12 and 24. There was a significant de-
crease in all parameters from baseline to weeks 12 and 24
in participants in both the individual and group program
(p<0.001 for all; t-test; Table 3). The decrease in body
weight and BMI from baseline to weeks 12 and 24 was
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TABLE 1
CHANGES IN ANTHROPOMETRIC PARAMETERS AND CARDIOVASCULAR RISK FACTORS FROM BASELINE
TO WEEKS 12 AND 24 IN 476 PARTICIPANTS IN THE INDIVIDUAL AND GROUP WEIGHT LOSS PROGRAM*
Parameters
Healthy weight-loss program (mean±SD)
p*
individual (n=233) group (n=243)
Baseline
age (years) 51.1 (14.0) 52.0 (13.8) 0.467
sex (men, %) 69 (28.4) 97 (40.2) 0.007†
waist (cm) 100.2 (13.2) 104.8 (14.7) 0.001
body height (cm) 166.8 (8.5) 170.1 (9.0) <0.001
body weight (kg) 85.9 (14.4) 94.7 (17.3) <0.001
body mass index (kg/m2) 30.9 (4.6) 32.7 (5.2) <0.001
systolic blood pressure (mmHg) 142.1 (21.9) 145.9 (21.3) 0.056
diastolic blood pressure (mmHg) 87.1 (11.4) 88.7 (10.7) 0.125
plasma glucose (mmol/L) 5.8 (1.8) 6.0 (1.8) 0.191
cholesterol (mmol/L) 6.0 (1.1) 6.1 (1.1) 0.294
Week 12
body weight (kg) 81.1 (13.6) 88.2 (15.6) <0.001
body mass index (kg/m2) 29.1 (4.4) 30.5 (4.7) 0.002
Week 24
body weight (kg) 78.4 (13.3) 82.5 (14.5) 0.001
body mass index (kg/m2) 28.1 (4.3)v 28.5 (4.4) 0.360
systolic blood pressure (mmHg) 133.2 (11.6) 135.4 (12.6) 0.045
diastolic blood pressure (mmHg) 83.5 (7.2) 84.9 (7.0) 0.023
plasma glucose (mmol/L) 5.1 (1.0) 5.4 (1.3) 0.033




NUMBER OF PARTICIPANTS IN THE INDIVIDUAL AND GROUP
WEIGHT LOSS PROGRAM ACCORDING TO THE PERCENTAGE
OF WEIGHT LOSS IN WEEKS 12 AND 24
Weight loss







0 4 (0.8) 3 (1.3) 1 (0.4)
0–5% 189 (39.7) 115 (49.4) 74 (30.5)
5–10% 236 (49.6) 100 (42.9) 136 (56.0)
>10% 47 (9.9) 15 (6.4) 32 (13.2)
Week 24
0 0 (0.0) 0 (0.0) 0 (0.0)
0–5% 56 (11.8) 47 (20.3) 9 (3.7)
5–10% 197 (41.5) 109 (47.0) 88 (36.2)
>10% 222 (46.7) 76 (32.8) 146 (60.1)
significantly greater in participants in the group pro-
gram than in participants in the individual program,
whereas the decrease in blood pressure, glucose, and cho-
lesterol was similar in both groups (Table 3). Partici-
pants in the group program lost 13% of their baseline
body weight and 12.8% of their BMI after 24 weeks,
whereas participants in the individual program lost 9%
of their baseline body weight and 9.1% of their BMI (Ta-
ble 3). To determine which groups mutually differed in
the mean values of monitored parameters, the Duncan
test for multiple comparisons was applied. At the begin-
ning of the program, men and women in individual and
group program significantly differed in their body weight
(Table 4). Men in the individual program did not differ in
systolic blood pressure from women in individual or par-
ticipants in the group program. Also, there were no dif-
ferences in glucose levels among men and women in indi-
vidual and group program. At week 12, women in the
individual program had the lowest BMI, whereas men in
the individual and group program and women in the
group program did not mutually differ in their BMI. Af-
ter 24 weeks, there was no difference in body weight and
blood glucose among men and women in two programs.
However, men in the group program had the greatest sys-
tolic and diastolic blood pressure, whereas men in the in-
dividual program and women in the individual and group
program did not mutually differ in their blood pressure
(Table 4). A comparison of the changes in body weight
and BMI in week 12 showed no significant difference be-
tween men in the individual program and women in the
group program (Table 5). There were no differences in
BMI between men and women in the individual program
either. At week 24, changes in body weight differed
among men and women in two programs. To confirm
that these differences results from the program and not
from the baseline differences, analysis of covariance
(ANCOVA) was carried out.
Participants in the individual program were signifi-
cantly different at baseline from participants in the group
program with respect to the waist circumference, body
height, body weight, and BMI, with participants in the
group program having greater values of these parame-
ters. To exclude the possibility that the differences in the
changes in monitored parameters were the result of the
baseline differences rather than the program, analysis of
covariance (AMCOVA) was applied with BMI and body
weight chosen as covariates (Figure 1). The dependency
of the changes on BMI was significant for all monitored
parameters, except for cholesterol, and the dependency
of changes in body weight on BMI was also significant
(p<0.001).
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TABLE 3
COMPARISON OF THE MEAN CHANGES IN PARAMETERS FROM BASELINE TO WEEKS 12 AND 24 IN 476 PARTICIPANTS
IN THE INDIVIDUAL AND GROUP WEIGHT LOSS PROGRAM*
Parameter
Change from baseline (mean±SD)
p†
individual program (n=233) group program (n=243)
Week 12
body weight (kg) –4.8 (3.3) –6.5 (3.4) <0.001
body mass index (kg/m2) –1.7 (1.2) –2.2 (1.2) <0.001
Week 24
body weight (kg) –7.6 (4.5) –12.2 (6.6) <0.001
body mass index (kg/m2) –2.7 (1.6) –4.2 (2.2) <0.001
systolic blood pressure (mmHg) –8.9 (15.5) –10.5 (13.6) 0.243
diastolic blood pressure (mmHg) –3.6 (8.0) –3.7 (7.6) 0.879
plasma glucose (mmol/L) –0.6 (1.0) –0.6 (0.9) 0.896
cholesterol (mmol/L) –0.6 (1.0) –0.7 (0.7) 0.706
* p<0.001 (t-test) for all changes from baseline to weeks 12 and 24 in both groups.
† t-test, between-group comparison.
Body mass index

















Fig. 1. Healthy Weight Loss Program Outcomes. Changes in body
weight with BMI as a covariate in 476 participants in Healthy
Weight Loss Program. White dots/line – participants working in-
dividually; black dots/line – participants working in groups;
analysis of covariance (ANCOVA).
The analysis also showed that the lines were not par-
allel (p=0.019). The two program groups were compared
at BMI of 27, 32, and 37. At BMI of 27, there was no sig-
nificant difference in weight loss between participants in
the individual program and those in the group program,
whereas at BMI values of 32 and 37, the differences were
significant (p<0.001). A similar result was obtained for
the changes in BMI after 12 weeks. Changes in body
weight and BMI after 24 weeks also depended on BMI
(p<0.001 for changes in both body weight and BMI). A
comparison of individual and group program based on
different BMI values in weeks 12 and 24 showed a signifi-
cant difference for the lowest, middle, and highest BMI
values. The participants with greater body weight and
BMI lost more weight working in groups, thereby being
more successful in reducing cardiovascular risk factors.
Discussion
We found that persons completing the Healthy Weight
Loss Program, which lasted 6 months and consisted of
education, psychological support, physical exercise, low
fat diet, and pharmacological treatment with orlistat,
significantly reduced their body weight, BMI, blood pres-
sure, glucose, and cholesterol. Furthermore, the decrease
in these parameters was greater in persons in the group
program than in persons opting for the individual pro-
gram of weight loss.
Many studies dealing with the problem of obesity
point to the importance of treating obesity in order to re-
duce health complications, first and foremost cardiovascu-
lar diseases and diabetes mellitus14–18. Pharmacological
treatment combined with a proper diet and regular exer-
cise provides a significant contribution in the treatment
of obesity as well as associated risk factors14. Our results
are in accordance with those obtained in previous re-
search14–18. In our study, all monitored values decreased
considerably in all participants of weight loss program.
Over 10% reduction in body weight after 6 months
was recorded in two-thirds of participants in the group
program and one-third of participants working individu-
ally. The participants who were attending the group
weight-loss program lowered their body weight, BMI,
blood pressure, glucose, and cholesterol more than those
who worked individually. Working in the group creates a
positive atmosphere of mutual support, which makes the
adoption of healthy habits and long-term control over
body weight easier, and the fact that participants who
chose to work in groups had greater body weight at base-
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TABLE 4
COMPARISON OF THE PARAMETERS IN MEN AND WOMEN IN THE INDIVIDUAL AND GROUP WEIGHT LOSS PROGRAM
AT BASELINE AND WEEKS 12 AND 24 *
Parameters
Men Women
individual (n=69) group (n=97) individual (n=164) group (n=146) p*
Baseline
age (years) 53.1 54.4 50.4 50.5 0.098
waist (cm) 108.91 111.21 96.82 100.42 <0.001
body height (cm) 175.31 176.21 163.4 165.9 <0.001
body weight (kg) 97.2 104.3 81.5 88.1 <0.001
body mas index (kg/m2) 31.61,2 33.7 30.62 32.01 <0.001
systolic blood pressure (mmHg) 144.61,2 149.81 141.22 143.42 0.019
diastolic blood pressure (mmHg) 87.9 90.3 86.8 87.6 0.098
glucose (mmol/L) 6.61 6.51 5.42 5.62 <0.001
cholesterol (mmol/L) 6.0 6.1 6.0 6.1 0.731
Week 12
body weight (kg) 91.2 96.7 77.1 82.4 <0.001
body mas index (kg/m2) 29.71 31.21 28.9 29.91 0.001
Week 24
body weight (kg) 88.11 90.11 74.52 77.42 <0.001
body mass index (kg/m2) 28.7 29.1 27.9 28.1 0.152
systolic blood pressure (mm Hg) 133.61 138.4 133.01 133.41 0.003
diastolic blood pressure (mm Hg) 84.01 86.3 83.21 84.11 0.010
glucose (mmol/L) 5.51 5.61 5.02 5.22 <0.001
cholesterol (mmol/L) 5.4 5.5 5.4 5.4 0.624
1,2 – same numbers denote groups with no significant differences between means (Duncan test for multiple comparison)
*ANOVA test.
line implies the need of obese individuals in the process of
losing weight to have the support of their environment.
Blood pressure decreased significantly in all partici-
pants without any differences between men and women
or between participants in the individual and those in
the group program; the differences depended on the
baseline blood pressure. A systematic review of the stud-
ies that followed the relation between the loss of extra
weight and high blood pressure, from 1966 to 2001,
showed that the loss of 10 kilograms decreases both sys-
tolic and diastolic blood by 4–6 mmHg15.
Decrease in blood glucose was greater in men than in
women, without any difference between the individual
and group program. However, the difference in the de-
crease of blood glucose level was greater where the base-
line values were higher; the decrease was greater in par-
ticipants in the individual program. The difference in the
reduction of cholesterol was noticed only in the depend-
ence on cholesterol values at the beginning of the pro-
gram. Given the fact that participants in the group pro-
gram had greater initial cholesterol values, they achieved
significantly greater decrease.
Orlistat was shown effective not only in the reduction
of body weight by reducing the absorption of fat from
food, but also in reduction of risk factors, such as in-
creased blood pressure, lipids, and sugar19–21. Further-
more, there are economic in addition to pharmacological
advantages in treating obesity with orlistat22. The effec-
tiveness of orlistat in combination with healthy nutrition
and regular physical activity, as fundamental guidelines
of our weight-loss program, allows the creation of ther-
apy models for a professional and organized approach in
the long-term treatment of obesity.
Extreme importance in treating obesity should be di-
rected towards family doctors and pharmacists23–26. They
are ideal for creating and realizing similar programs of
healthy weight loss because individuals who are over-
weight most often come to them in search for expert help
in loosing the extra weight. So far, their engagement has
not been sufficient in the implementation of a unique al-
gorithm for treating obesity. Several studies have con-
firmed that it is these types of programs, as well as
pharmacotherapy with orlistat in the area of primary
healthcare, that are invaluable for the successful treat-
ment of obesity and the prevention of the development of
serious clinical complications, including cardiovascular
diseases20–31.
The present study based on an applied program for
treating obesity aimed to provide a paradigm for the or-
ganization of future obesity treatment programs, includ-
ing prevention of obesity and obesity-related health com-
plications, especially cardiovascular diseases.
The results of and experience in our program of
healthy weight loss confirm the need for obesity treat-
ment to be approached gradually, with objectives that are
realistic and weight loss that increases every three mon-
ths. Thus, disappointment by unrealistic expectations is
avoided, as well as the emergence of the yoyo effect due
to an overly rapid loss of weight. The general health con-
dition of our participants who lost 5–10% or more of the
initial body weight was improved, as confirmed by the
values of blood pressure, glucose, and cholesterol, which
returned to normal by the end of the program.
Study limitation
There are some limitation in the study that need to be
acknowledged and addressed regarding the lack of ran-
domization into individual or group treatment program.
Conclusion
Our study showed that attending the 6-month pro-
gram for treating obesity had effect on body weight and
cardiovascular risk factors in individuals on orlistat ther-
apy, regardless of whether or not the program was car-
ried out in a group or individually, even though all moni-
tored parameters decreased more in participants in the
group program, which in itself contained elements of the
behavioural approach to treatment. Body weight, BMI,
systolic and diastolic blood pressure, blood glucose, and
cholesterol were significantly lower at the end of pro-
gram in comparison with baseline values in all partici-
pants. The presented program of healthy weight loss
could be a long-term solution in treating obesity and pre-
venting diabetes mellitus and cardiovascular diseases,
frequently related to excessive body weight. For the final
evaluation of the Healthy Weight Loss Program, the
present research should be continued and new similar
projects initiated on a larger sample for a longer time.
Treatment of obesity should include family physicians,
pharmacists, and other interested parties, from civil soci-
ety to health and pension funds to state institutions, to
increase the effectiveness of the treatment of obesity and
prevention of obesity-related morbidity and mortality.
Our study showed that attending the 6-month program
for treating obesity had effect on body weight and cardio-
vascular risk factors in individuals regardless of whether
or not the program was carried out in a group or individ-
ually, even though all monitored parameters decreased
more in participants in the group program, which in it-
self contained elements of the behavioural approach to
treatment and because of its effectiveness should be con-
sidered one of the most promising models for future de-
velopment of weight loss programs.
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U^INCI LIJE^ENJA PRETILOSTI NA KARDIOVASKULARNE RIZI^NE ^IMBENIKE: USPOREDBA
INDIVIDUALNOG I GRUPNOG PROGRAMA GUBITKA TJELESNE TE@INE – SUBANALIZA
HRVATSKOG PROGRAMA ZDRAVOG MR[AVLJENJA
S A @ E T A K
Prevencija debljine poma`e u redukciji morbiditeta i mortaliteta kardiovaskularnih oboljenja. U Hrvatskoj, preko
polovine odrasle populacije ima prekomjernu tjelesnu te`inu koja je dokazano terapijski najtvrdokorniji promjenjivi
kardiovaskularni rizik. Obzirom na neupitne temeljne postulate lije~enja debljine i prethodno dokazanu u~inkovitost
terapijskog pristupa kori{tenog u studiji, ova je subanaliza usmjerena utvr|ivanju razlika u u~inkovitosti grupnog i
individualnog programa mr{avljenja na redukciju ~imbenika kardiovaskularnog pobola. U komparativnu studiju uklju-
~eno je 476 odraslih osoba s indeksom tjelesne mase (ITM) >30 ili >28 uz dodatne rizike: povi{ene vrijednosti krvnog
tlaka, glukoze u plazmi i kolesterola. U~esnici studije uklju~eni su u dva razli~ita programa lije~enja sni`enja tjelesne
te`ine koji su trajali {est mjeseci: grupni (n=243) ili individualni (n=233) program koji su se sastojali od edukacije,
dijete s niskim sadr`ajem masno}e, farmakolo{kog lije~enja orlistatom, psiholo{ke potpore i tjelovje`be. Tjelesna te`ina,
indeks tjelesne mase, krvni tlak, glukoza i kolesterol u krvi mjereni su u svih sudionika na po~etku studije, nakon 3, te
nakon 6 mjeseci lije~enja. Prosje~an gubitak te`ine u grupnom programu iznosio je 12,2 kg (13%), a u individualnom
programu 7,6 kg (9%) kg. Uz smanjenje indeksa tjelesne mase postignuto je tako|er i zna~ajno sni`enje vrijednosti
razine kolesterola u krvi, glukoze u plazmi i krvnog tlaka u odnosu na bazalne vrijednosti na po~etku studije. Nakon 6
mjeseci lije~enja u svih sudionika studije postignute su normalne vrijednosti razine kolesterola u krvi, glukoze u plazmi
i krvnog tlaka (p<0.001 u svih). Primijenjen program mr{avljenja omogu}io je u~inkovit i zdrav gubitak tjelesne te`ine
tijekom razdoblja od 6 mjeseci u obje analizirane skupine, ali je grupnim programom postignuto ve}e smanjenje tjelesne
te`ine, indeksa tjelesne mase, krvnog tlaka, glukoze u plazmi i kolesterola. Uz potrebu za dodatnom potvrdom ovih
rezultata, ~ini se da bi upravo provedba grupnih programa mr{avljenja mogla predstavljati osnov budu}e globalne stra-
tegije u lije~enju debljine.
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